Carrick Therapeutics, Inc. () Press Releases https://www.carricktherapeutics.com/investors/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/carricktherapeutics/files/theme/images/logo-sm.png Carrick Therapeutics, Inc. Logo /investors Equisolve Investor Relations Suite <![CDATA[Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/27/carrick-therapeutics-announces-positive-results-from-phase Wed, 10 Dec 25 13:30:00 -0500 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/27/carrick-therapeutics-announces-positive-results-from-phase <![CDATA[Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/26/carrick-therapeutics-announces-new-clinical-data-supporting Thu, 15 May 25 07:00:00 -0400 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/26/carrick-therapeutics-announces-new-clinical-data-supporting <![CDATA[Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase Mon, 23 Sep 24 08:00:00 -0400 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase <![CDATA[Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/24/carrick-therapeutics-establishes-new-headquarters-in Wed, 05 Jun 24 08:00:00 -0400 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/24/carrick-therapeutics-establishes-new-headquarters-in <![CDATA[Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/23/carrick-therapeutics-announces-first-patient-dosed-in-phase Wed, 14 Feb 24 08:00:00 -0500 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/23/carrick-therapeutics-announces-first-patient-dosed-in-phase <![CDATA[Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/22/carrick-therapeutics-announces-first-patient-dosed-in-phase Fri, 15 Dec 23 08:00:00 -0500 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/22/carrick-therapeutics-announces-first-patient-dosed-in-phase <![CDATA[Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/21/carrick-therapeutics-announces-first-patient-dosed-in-phase Wed, 18 Oct 23 09:00:00 -0400 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/21/carrick-therapeutics-announces-first-patient-dosed-in-phase <![CDATA[Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind Thu, 07 Sep 23 08:00:00 -0400 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind <![CDATA[Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/19/carrick-therapeutics-announces-clinical-trial-collaboration Thu, 06 Jul 23 09:00:00 -0400 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/19/carrick-therapeutics-announces-clinical-trial-collaboration <![CDATA[Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination]]> https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/18/carrick-therapeutics-and-the-menarini-group-announce Mon, 19 Dec 22 09:48:00 -0500 https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/18/carrick-therapeutics-and-the-menarini-group-announce